X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 4c; Cash and Cash Equivalents of $77.7M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to X4 Pharmaceuticals (XFOR) Misses Q3 EPS by 4c; Cash and Cash Equivalents of $77.7M

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

November 4, 2021 9:01 AM EDT

Data continue to support mavorixafors potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenströms macroglobulinemia

Discovery of new prevalent WHIM variant further validates the companys U.S. WHIM prevalence projections

Company to host an Investor Day on December 16 with key opinion leaders leading discussions on four poster presentations and additional clinical and scientific data

Conference call today at 9:05 a.m. ET

BOSTON, Nov. 04,... More